pripheral neuropathy. Drug-induced polyneuropathy
Conditions
Interventions
Intervention 1: Intervention group1 will receive Venlafaxine capsules 37.5 mg every 24 hours for a month. Intervention 2: Control group will receive placebo every24 hours for a month. Intervention 3
Treatment - Drugs
Placebo
Intervention group1 will receive Venlafaxine capsules 37.5 mg every 24 hours for a month
Control group will receive placebo every24 hours for a month
Intervention group 2 will receive duloxetine capsules 30 mg every 24 hours for a month
Sponsors
Vice chancellor for research, Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were: Patients with cancer and with peripheral neuropathy caused by chemotherapy; Patient written consent; No uncontrolled blood pressure, diabetes, addiction. Exclusion criteria: Patients treated with tamoxifen; Incidence of intolerable side effects; No on time and correct use of medicines; No patient cooperation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of neuropathy. Timepoint: The first, second week and end of the study (fourth week). Method of measurement: Based on the visual analogue scale (VAS), Sheehan Disability Scale, Brief Pain Inventory, Depression Inventory (Mood), Beck Depression Inventory (BD1-11), Clinical Global Impression Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAvisa Alavi
Kermanshah University of Medical Sciences
Outcome results
None listed